OncoImmunity AS has been acquired by renowned Japanese IT and network company, NEC Corporate. OncoImmunity AS develops software that identifies neoantigen targets for truly personalized cancer vaccines, cell therapies and optimal patient selection for cancer immunotherapy clinical trials.
GJE provided OncoImmunity AS with IP-related due diligence support during the acquisition and continues to manage the company’s patent portfolio. The GJE team is led by partner Matt Hoyles.
To read the full press release, please follow this link.
Related resources
Cultivating Christmas: Lab-To-Table Delicacies You Won’t Want to Miss This Year!
As we approach the end of 2023, the lure of innovative high-tech food products seems greater than ever....
Olympic Games Paris 2024
On July 26th, the world came together to witness the opening ceremony of the 2024 Olympic Games, marking...
UK Becomes Even More Attractive for First Filings in Computing and Telecomms
Following an announcement earlier in the year that the UK IPO will be outsourcing searches to the EPO (see Ross’ article here), the UK IPO have expanded this to the computing and telecommunications fields (see announcement here). Where UK applications are filed in these fields, there will be a pot luck process as to whether an application is searched by...